“…AB2 was further divided into N-and C-terminal peptides peptide derived from N-terminus of AB2 (AB2N) and peptide derived from C-terminus of AB2 (AB2C; Chempeptide Ltd., China). A mutant of AB2N was designed by replacing the key amino acids in the YSRLGF motif with glycine, making it GSRGGG (Wald et al, 2017), which we refer to as peptide AB2N with mutation Abbreviations: AB2, Ambn-exon 5 derived peptide; AB2C, Peptide derived from C-terminus of AB2; AB2N, Peptide derived from N-terminus of AB2; AB2N-GGG, Peptide AB2N with mutation p.Y67G_L70G_F72G; AB4, Ambn-exon 6 derived peptide; AI, Amelogenesis imperfecta; Ambn/rAmbn, Ameloblastin/recombinant ameloblastin; AmbnΔ5, Ambn p.Y67_Q103del; AmbnΔ6, Ambn p.P104_V168del; Amel/rAmel, Amelogenin/recombinant amelogenin; Co-IP, Co-immunoprecipitation; EMP, Enamel matrix protein; MCC, Manders' colocalization coefficient; SDS-PAGE, Sodium dodecyl sulfate polyacrylamide gel electrophoresis; TRAP, Tyrosine rich amelogenin polypeptide. p.Y67G_L70G_F72G (AB2N-GGG; Biomertech, United States; Supplementary Figures 3, 4; Supplementary Table 1).…”